AtriCure, Inc. (NASDAQ:ATRC) Shares Bought by Hood River Capital Management LLC

Hood River Capital Management LLC boosted its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 3.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,923,731 shares of the medical device company's stock after acquiring an additional 93,131 shares during the quarter. AtriCure accounts for approximately 1.3% of Hood River Capital Management LLC's investment portfolio, making the stock its 23rd biggest position. Hood River Capital Management LLC owned 6.00% of AtriCure worth $89,349,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ATRC. Geode Capital Management LLC boosted its stake in shares of AtriCure by 2.9% in the third quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock valued at $32,326,000 after purchasing an additional 32,676 shares during the period. Silver Oak Securities Incorporated purchased a new position in AtriCure in the 4th quarter valued at approximately $220,000. JPMorgan Chase & Co. boosted its position in AtriCure by 43.1% in the 4th quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock valued at $11,160,000 after buying an additional 110,039 shares during the period. Calamos Advisors LLC grew its stake in shares of AtriCure by 27.9% in the fourth quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company's stock worth $3,382,000 after acquiring an additional 24,147 shares in the last quarter. Finally, M&T Bank Corp purchased a new stake in shares of AtriCure during the fourth quarter worth $208,000. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Stock Up 0.5 %

Shares of NASDAQ ATRC traded up $0.16 during mid-day trading on Monday, reaching $33.56. The company had a trading volume of 327,234 shares, compared to its average volume of 654,625. The firm has a 50 day simple moving average of $34.32 and a two-hundred day simple moving average of $34.66. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $43.11. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.66 billion, a P/E ratio of -35.36 and a beta of 1.65.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on ATRC shares. JPMorgan Chase & Co. lowered their target price on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, March 27th. Canaccord Genuity Group lowered their price objective on AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. Piper Sandler raised their target price on shares of AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. JMP Securities reiterated a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a report on Monday, February 10th. Finally, Needham & Company LLC restated a "buy" rating and issued a $51.00 price objective on shares of AtriCure in a report on Thursday, March 27th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, AtriCure currently has a consensus rating of "Moderate Buy" and an average price target of $49.44.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.